Dr. Martin F Bachmann
Dr. Martin Bachmann has a PhD and a Master’s degree with Honors from the Eigenössichen Technischen - Hochschule Zürich (ETH) in Switzerland. He completed both degrees with distinction. His PhD and his Master’s thesis were honoured with ETH Silver Medals in 1995 and 1991, respectively. Martin carried out his PhD research in the lab of the Nobel Laureate Prof. Rolf Zinkernagel and continued with post-doctoral work at the Princess Margaret Hospital, Toronto in the lab of Prof. Pam Ohashi.
He then became a member of the Basel Institute for Immunology. From 2002-2012, he was Chief Scientific Officer at Cytos Biotechnology Ag, where he built up a research group of up to 50 people. In 2012, he returned to academia and is currently appointed as Professor of Immunology at the University of Bern and Oxford. He is also Professor of Vaccinology at Anhui Agricultural University, China.
Dr. Bachmann founded a number of biotechnology companies including Saiba GmbH, Evax AG, Hypopet AG and HelaVax GmbH in the fields of therapeutic vaccines and immune-modulation. He also serves on the Scientific Advisory board of several companies and institutions. At the age of 50, Dr. Bachmann has published more than 250 peer-reviewed scientific papers, his publication h-index is 95 and he is the inventor of more than 50 filed or granted patents. Dr. Bachmann has brought 7 compounds from the mouse model into man.
